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Abstract
Epidemiological studies suggest that allergy risk is preferentially transmitted through moth-
ers. This can be due to genomic imprinting, where the phenotype effect of an allele depends
on its parental origin, or due to maternal effects reflecting the maternal genome's influence
on the child during prenatal development. Loss-of-function mutations in the filaggrin gene
(FLG) cause skin barrier deficiency and strongly predispose to atopic dermatitis (AD). We in-
vestigated the 4 most prevalent European FLGmutations (c.2282del4, p.R501X, p.R2447X,
and p.S3247X) in two samples including 759 and 450 AD families. We used the multinomial
and maximum-likelihood approach implemented in the PREMIM/EMIM tool to model par-
ent-of-origin effects. Beyond the known role of FLG inheritance in AD (R1meta-analysis = 2.4,
P = 1.0 x 10−36), we observed a strong maternal FLG genotype effect that was consistent in
both independent family sets and for all 4 mutations analysed. Overall, children of FLG-car-
rier mothers had a 1.5-fold increased AD risk (S1 = 1.50, Pmeta-analysis = 8.4 x 10
−8). Our
data point to two independent and additive effects of FLGmutations: i) carrying a mutation
and ii) having a mutation carrier mother. The maternal genotype effect was independent of
mutation inheritance and can be seen as a non-genetic transmission of a genetic effect.
The FLGmaternal effect was observed only when mothers had allergic sensitization (ele-
vated allergen-specific IgE antibody plasma levels), suggesting that FLGmutation-induced
systemic immune responses in the mother may influence AD risk in the child. Notably, the
maternal effect reported here was stronger than most common genetic risk factors for AD
recently identified through genome-wide association studies (GWAS). Our study highlights
the power of family-based studies in the identification of new etiological mechanisms and
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reveals, for the first time, a direct influence of the maternal genotype on the offspring’s sus-
ceptibility to a common human disease.
Author Summary
Most human diseases are caused by a combination of multiple environmental and genetic
influences. The widely used case/control approach aims to identify disease risk genes by
comparing the genetic constitution of affected and healthy individuals. Although success-
ful, this approach ignores additional mechanisms influencing disease risk. Here, we stud-
ied mutations in the filaggrin gene (FLG), which are strong risk factors for atopic
dermatitis (AD) and allergies, in a large number of families with AD. We found that FLG
mutations in the mother, not the father, increased the AD risk of the children, even if the
child did not inherit the mutation. Thus, our study revealed, for the first time, a direct in-
fluence of a maternal mutation on the child’s risk for a common disease. The maternal
FLG effect was only found when the mothers were allergic, and was absent in families of
non-allergic mothers. This finding suggests that FLG-induced changes in the maternal im-
mune response shape the child’s immune system during pregnancy and increase the
child’s risk for AD. Our study indicates that maternal FLGmutations act as strong envi-
ronmental risk factors for the child and highlights the potential of family-based studies in
uncovering novel disease mechanisms in medical genetics.
Introduction
Atopic dermatitis (AD, eczema) is a chronic inflammatory skin disease with 10–20% preva-
lence in industrialized countries. The etiology of AD is complex, with multiple genetic and en-
vironmental factors influencing disease risk. Genome-wide association studies (GWAS) have
successfully identified common genetic variants predisposing to AD, but the effect of these risk
loci is small and altogether only account for a fraction of the disease heritability.
The filaggrin gene (FLG) encodes a structural protein playing a critical role in the terminal
differentiation of the epidermis and in skin barrier function [1]. Loss-of-function mutations in
FLG were identified as the cause of ichthyosis vulgaris, a common Mendelian trait character-
ized by dry, scaly skin and frequent AD [2]. Subsequent studies revealed that FLGmutations
also strongly predispose to AD [3,4]. This observation has been widely replicated, rendering
FLG the strongest and best characterized AD risk locus to date [1]. Overall, evidence from
human and animal studies demonstrated that filaggrin deficiency results in altered skin struc-
ture, impaired barrier function and enhanced antigen penetration through the skin, leading to
the production of allergen-specific IgE antibodies (specific sensitization) and AD [5–7].
Epidemiological studies on allergic diseases have shown that maternal allergy is a stronger
risk factor for the child than paternal allergy [8,9], although some conflicting results have been
reported for AD [10,11]. The molecular basis of this preferential maternal transmission of al-
lergy risk is currently unknown but it can potentially occur through two different biological
mechanisms, genomic imprinting or direct maternal genotype effects. In genomic imprinting,
either the maternally or the paternally inherited allele is expressed while the alternate allele is
silenced. Thus, the effect of an allele depends on its parental origin resulting in phenotypic dif-
ferences between reciprocal heterozygotes (parent-of-origin effects) [12,13]. Recent studies
have demonstrated that parent-of-origin effects in complex diseases can be due to genetic
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variation in imprinted genes [12,13]. Alternatively, maternal genotype effects occur when the
maternal genotype directly influences the child’s phenotype. This effect is independent of the
child’s own genotype and occurs through the maternally provided environment during prena-
tal development. Maternal genotype effects can lead to phenotypic differences between recipro-
cal heterozygotes and are thus considered parent-of-origin effects [13,14].
We hypothesized that loss-of-function mutations in FLGmay show parent-of-origin effects.
Analysis of 2 large family-based cohorts strongly supports that maternal FLGmutations direct-
ly increase AD risk in the children.
Results
Allelic heterogeneity and population-specific mutations in FLG
To systematically identify loss-of-function variants at the FLG locus, we used data of the
Exome Aggregation Consortium (ExAC [15]), which includes whole exome sequencing results
of 61,486 individuals. Filtering by frameshift or non-sense mutations revealed 254 loss-of-func-
tion mutations in the gene (S1 Table). The majority of FLGmutations were very rare, 227 of
254 FLGmutations (89,4%) had an allele frequency (AF)< 0.0001. Further analysis revealed
the presence of population-specific mutations. For example, the p.L4022X mutation was com-
mon in East Asia (AF = 0.02) but absent from all other populations studied. This data confirms
and extends previous reports of allelic heterogeneity and population-specific mutations in FLG
[1].
In the European (non-Finnish) population ExAC reported 146 loss-of-function mutations
with a combined AF of 0.052. Of these, the 4 most prevalent mutations, accounting for 86% of
all mutant alleles in this population, were selected for genotyping in the present study:
p.761fsX35 (c.2282_2285delCAGT; rs558269137, referred to as c.2282del4), p.R501X
(c.1501C>T; rs61816761), p.R2447X (c.7339C>T; rs138726443), and p.S3247X (c.9740C>A;
rs150597413).
FLGmutations are strong risk factors for AD
The 4 selected mutations were genotyped in 759 complete nuclear families from Central Eu-
rope recruited through one or more children with AD (methods and Table 1). The allele fre-
quencies in the founders were in good agreement with previous studies (0.059, 0.034, 0.01 and
0.002 for c.2282del4, p.R501X, p.R2447X and p.S3247X, respectively) [16,17].
As previously reported, FLGmutations showed a strong over-transmission from heterozy-
gote parents to AD-affected children in a Transmission Disequilibrium Test (TDT; Table 2
[16,17]). We observed no linkage disequilibrium among FLGmutations, since each mutation
was on a different haplotype and 2 different mutations never occurred together in the same
haplotype (S2 Table). Since previous studies reported that these 4 loss-of-function FLGmuta-
tions have the same effect on AD risk, we decided to merge all variants into a combined geno-
type [4]. This enabled us to work with one common instead of 4 low-frequency variants.
Unless stated otherwise, the results presented below refer to the combined genotype.
Direct maternal genotype effect of FLGmutations
Testing for parent-of-origin effects was performed with the PREMIM/EMIM software. This
tool uses a multinomial model-based maximum-likelihood approach for flexible modelling of
parent-of-origin effects (see methods) [18,19]. In order to increase power, we included FLG ge-
notypes of 1147 unrelated AD cases and 3339 population-based controls. This set of unrelated
individuals does not provide information on parent-of-origin effects, but increases the power
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to detect them by improving the estimation of genotype frequencies in the general population
(see methods) [18,19].
We performed a step-by-step analysis starting with a basic genetic model and successively
including additional risk parameters modelling parent-of-origin effects. The basic scenario ig-
nored the available parental genotypes and tested the effect of the child´s genotype on his own
phenotype. As expected, we observed large effects with relative risks of 3.1 for heterozygous
(R1 parameter) and 10.5 for homozygous FLGmutation carriers (R2 parameter) (Child Geno-
type or CG model; R1 = 3.1, R2 = 10.5; PCG = 5.9 x 10
−74; Table 3).
Next maternal genotype effects were modelled by including an additional parameter, S1, to
estimate the relative AD risk of children whose mother carried a FLGmutation. Children of
FLGmutation-carrier mothers had a striking 1.55 fold increase in AD risk independently of
their own genotype (Mother-Child Genotype model or MCG; R1 = 2.57, R2 = 7.97, S1 = 1.55;
PMCG = 2.7 x 10
−77; Table 3). A comparison of the Child Genotype and the Mother-Child Ge-
notype models by a likelihood-ratio test, strongly supported the existence of a maternal geno-
type effect (PMCG vs CG = 5.0 x 10
−6). In addition, we observed no evidence of interaction
between the child and maternal genotypes, indicating that carrying a mutation and having a
Table 1. Study populations.
Central European Northern European
Families Total number of families 759 450
Number of complete nuclear families 759 325
- families with 1 affected child (Trio) 323 35
- families with 2 affected siblings (ASP) 399 235
- families with > 2 affected siblings 37 55
Number of incomplete families 0 125
Total number of affected children 1209 680
Unrelated individuals Number of cases 1147 0
Number of population-based controlsa 3339 1854
a All population-based controls were included in the study irrespective of AD status. ASP refers to affected sib pairs.
doi:10.1371/journal.pgen.1005076.t001
Table 2. Results of the transmission disequilibrium test.
Central European Northern European
Mutation A1a A2b Freqc T / Ud ORe Pf Freqc T / Ud ORe Pf
c.2282del4 del Wild type 0.059 189 / 91 2.08 < 10−6 0.047 83 / 40 2.07 7.26 x 10−5
p.R501X T C 0.034 97 / 47 2.06 5.70 x 10−5 0.012 27 / 13 2.08 0.058
p.R2447X T C 0.010 29 / 17 1.71 0.27 0.014 8 / 22 0.36 0.01
p.S3247X A C 0.002 6 / 1 6 0.31 0.004 8 / 6 1.33 1
Combined Mutation Wild type 0.105 316 / 150 2.11 < 10−6 0.085 125 / 78 1.60 0.001
a A1 is the mutant allele.
b A2 is the wild type allele.
c Allele frequency of A1 in the family founders.
d Number of transmitted (T) and un-transmitted (U) A1 alleles.
e Odds ratio calculated as the ratio of transmitted versus un-transmitted alleles.
f Empirical p value calculated by flipping transmitted/untransmitted status in order to account for multiple affected siblings in each family.
doi:10.1371/journal.pgen.1005076.t002
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mutation carrier mother are independent risk factors with additive effect on disease risk (S3
Table and methods). Thus, children with both risk factors, i.e. carrying a FLGmutation and
having a mutation carrier mother, have a nearly 4-fold increased disease risk (R1 x S1 = 3.6).
Importantly, both genomic imprinting and maternal genotype effects can lead to similar
patterns of parent-of-origin effects and specific tests need to performed to distinguish them
[13,14]. Finally, we tested an imprinting model by including the imprinting parameter, Im,
which represents the relative risk of the child when inheriting a mutant allele from the mother
as opposed to the father. A comparison with the Child Genotype model provided marginal
support for the presence of imprinting (PIm vs CG = 0.047; Table 3). In order to test which par-
ent-of-origin scenario better fits our data we performed comparisons versus a full model con-
taining all risk parameter (R1, R2, S1 and Im). Interestingly, adding the maternal genotype
parameter S1 to a model already containing Im resulted in a significantly better model
(Table 4; p = 3.2 x 10−6). On the contrary, adding Im to a model already containing S1 provided
only a marginal improvement (p = 0.03). These results favour the existence of a direct maternal
genotype effect of FLG.
Table 3. Parent-of-origin analysis of the combined FLG mutations.
Children Genotype model (CG)
Study R1 (CI) R2 (CI) S1 (CI) Im (CI) Pnull
a -
Central Europe 3.10 (2.68–3.59) 10.5 (7.20–15.36) - - 5.9 x 10−74 -
Northern Europe 2.44 (1.95–3.06) 7.37 (3.37–15.81) - - 9.23 x
10−17
-
Meta-analysis
Pmeta
c
2.89 (2.56–3.27) 2.8 x
10−65
9.80 (6.97–13.77)2.1 x
10−39
- - - -
Phet
d 0.08 0.41
Maternal Child Genotype model (MCG)
Study R1 (CI) R2 (CI) S1 (CI) Im (CI) Pnull
a PMCG vs
CG
b
Central Europe 2.57 (2.18–3.04) 7.97 (5.36–11.87) 1.55 (1.29–1.87) - 2.7 x 10−77 5.0 x 10−6
Northern Europe 2.13 (1.67–2.72) 5.89 (2.67–12.97) 1.42 (1.11–1.82) - 1.42 x
10−17
0.005
Meta-analysis
Pmeta
c
2.43 (2.11–2.78) 1.0 x
10−36
7.50 (5.26–10.70) 1.2 x
10−28
1.50 (1.29–1.74) 8.4 x
10−8
- - -
Phet
d 0.21 0.50 0.58
Imprinting model (Im)
Study R1 (CI) R2 (CI) S1 (CI) Im (CI) Pnull
a PIm vs CG
b
Central Europe 2.70 (2.19–3.31) 8.06 (5.09–12.78) - 1.30 (1.00–1.69) 1.2 x 10−73 0.047
Northern Europe 2.19 (1.63–2.95) 5.97 (2.56–13.92) - 1.23 (0.86–1.75) 3.22 x
10−16
0.25
Meta-analysis
Pmeta
c
2.52 (2.13–2.99) 1.4 x
10−26
7.53 (5.02–11.28) 1.4 x
10−22
- 1.28 (1.03–1.57)
0.02
- -
Phet
d 0.26 0.54 0.80
a P value for the comparison of each model versus the null model with no effects.
b P value for the comparison of each model versus the Child Genotype model.
c P value for the meta-analysis of each estimated parameter (see methods). CI indicates 95% confidence interval.
d P value for a test of heterogeneity. All results correspond to the combined FLG mutations.
doi:10.1371/journal.pgen.1005076.t003
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Replication in an independent sample and meta-analysis
We aimed to replicate our findings by examining the same 4 FLGmutations in an independent
Northern European population including 450 AD families and 1854 population-based control
individuals (methods and Table 1) [17,20–22]. Step-by-step analysis with PREMIM/EMIM
again supported a maternal genotype effect. The genotypes of both children and mothers had
an independent effect on AD risk, and children of FLG-carrier mothers showed a 1.4 fold in-
creased risk (R1 = 2.13, R2 = 5.89, S1 = 1.42; PMCG = 1.4 x 10
−17; PMCG vs CG = 0.005; Table 3
and S3 Table). Importantly, the results obtained were consistent in both populations studied
providing strong support to the existence of maternal genotype effects on FLG.
A meta-analysis was performed using the inverse variance method as implemented in
METAL [23], which uses the effects estimates and standard errors from each risk parameter.
This revealed a highly significant 1.5 fold increased AD risk in children of FLG-carrier mothers
(S1meta-analysis = 1.50; P = 8.4 x 10
−8; Table 3).
FLGmutations are more frequent in mothers than in fathers
Analysis of parental genotypes revealed a higher prevalence of FLGmutations in mothers than
in fathers in both study populations (Fig. 1). This is consistent with the maternal genotype ef-
fect observed. Additionally the frequency of FLGmutations in the parental population (moth-
ers and fathers together) was remarkably higher than in population-based controls of
unknown phenotype. This is likely due to the recruitment of families with multiple affected
children leading to a parental population enriched in strong genetic risk factors.
Robustness of the FLGmaternal effect
At this stage we considered the potential weaknesses of our study in order to discard false posi-
tives due to methodological issues and to gain further support to the existence of a FLGmater-
nal genotype effect.
We analysed the FLG c.2282del4, p.R501X and p.R2247X mutations independently (this
was not possible for p.S3247X since it was too rare). The maternal effect and the increased fre-
quency of mutations in mothers were found for all 3 mutations in both study populations (S4
Table and S5 Table). This suggests that the maternal effect is not specific to a given variant but
a general characteristic of FLG loss-of-function mutations.
Table 4. Comparison of the MCG and Imprinting models with the full model.
Parameters included Central European study Northern European study
Model R1 R2 Im S1 lnlik Pnulla PCGb Pfullc lnlik Pnulla PCGb Pfullc
Null - - - - −3378.5 −1376.3
CG + + - - −3209.89 5.9 x 10–74 −1343.5 x 10−17
MG + + - + −3199.46 2.7 x 10−77 5.0 x 10−06 2.9 x 10−02 −1339.8 1.4 x 10−17 0.005 0.162
Im + + + - −3207.92 1.2 x 10−73 4.7 x 10−02 3.2 x 10−06 −1342.3 3.3 x 10−16 0.25 0.004
Full + + + + −3197.07 2.9 x 10−77 2.7 x 10−06 −1339.5 3.1 x 10−17 0.008
The “+” and “-” symbols indicate whether a given risk parameter was included or excluded in the corresponding model. lnlik is the maximized ln likelihood
for each model.
a P value for the comparison of each model versus the null model with no effects.
b P value for the comparison of each model versus the child genotype model including R1 and R2.
c P value for the comparison with the full model including all risk parameters (R1, R2, S1, S2, and Im).
doi:10.1371/journal.pgen.1005076.t004
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In the populations studied, mothers typically have a more prominent role than fathers in
children’s health care [24]. We hypothesized that preferential ascertainment of AD-affected
mothers carrying FLGmutations may be the cause of the observed maternal effect. Indeed, we
observed a higher frequency of AD-affected mothers than fathers, which could be due to a gen-
uine maternal effect or to ascertainment bias (AD prevalence in Central European mothers =
0.23 and fathers = 0.12; Northern European mothers = 0.35 and fathers = 0.19). In order to
Fig 1. Frequency of FLGmutations in fathers, mothers, individuals with atopic dermatitis and controls. Allele and genotype frequencies of the
combined FLG-mutations in fathers and mothers were calculated using all available parents. AD refers to the frequency in the AD-affected children including
the families and the unrelated AD-cases (available only in the Central European study). Frequency in controls corresponds to population-based individuals
with unknown disease status. Results of the Central and Northern European populations are shown in panels A and B, respectively.
doi:10.1371/journal.pgen.1005076.g001
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avoid this potential bias we repeated our analysis including only families in which both parents
had a negative history of AD. Importantly, the maternal genotype effect remained strong and
significant in the remaining population (Meta-S1 = 1.38; P = 0.003; S6 Table).
We also tested the potential effect of the paternal FLG genotype on the children. Since this
option is not available in PREMIM/EMIM, we performed the analysis after exchanging the pa-
ternal and maternal genotypes on our genotype files. This analysis revealed no significant effect
of the paternal FLG status (S7 Table).
A large proportion of the families included in the present study (60%) were recruited
through an affected sib pair. Aiming to maximize power, all previous analyses were performed
considering all affected siblings as independent individuals which may lead to biased risk pa-
rameter estimates. We therefore repeated the analysis including only one affected child per
family and found that the magnitude of the maternal effect remained constant in this set of in-
dependent trios (S1meta-analysis = 1.45; P = 1.1 x 10
−4; S8 Table).
Potential influence of maternal immunity
Filaggrin has a major role in cutaneous barrier function [1]. According to publicly available
datasets [25–27] FLG expression is highest in skin and absent in tissues relevant for mother-
child interactions such as uterus, placenta, or mammary gland (S1 Fig. and S2 Fig.). However,
recent studies demonstrated that FLGmutations result in increased antigen penetration
through the skin and the production of allergen-specific antibodies (IgE, specific sensitization)
[6,7,28]. Thus, we hypothesized that systemic inflammatory responses in FLG carrier mothers
may influence AD risk in children via feto-maternal immune crosstalk.
All available maternal plasma samples from the Central European study were therefore test-
ed for the presence of allergen-specific IgE, which is a well-characterized biochemical marker
of allergy [29]. We performed a stratified analysis in 253 families with and 311 families without
maternal specific sensitization. In the families with maternal specific sensitization (+Mat_sens)
we observed a strong maternal genotype (S1 = 1.63; PMCG vs CG = 0.005) and a weak child geno-
type effect (R1 = 1.37; Pnull = 0.03; Table 5). This was consistent with a marginal over-trans-
mission of FLGmutations from parents to affected offspring in a transmission disequilibrium
test (TDT, transmitted (T): untransmitted (U) = 97:65, P = 0.04; Table 6). In contrast, the op-
posite pattern was observed in the group of families with non-allergic mothers (−Mat_sens).
Table 5. Parent-of-origin-analysis analysis stratified by maternal specific sensitization.
Children Genotype model (CG)
Group na R1 (CI) R2 (CI) S1 (CI) Pnull
b PMCG vs CG
c
+Mat_sens 253 1.37 (0.97–1.94) 2.98 (1.19–7.45) - 0.03 -
−Mat_sens 311 2.30 (1.64–3.22) 7.19 (3.77–13.7) - 9.9 x 10−11 -
Maternal Child Genotype model (MCG)
Group na R1 (CI) R2 (CI) S1 (CI) Pnull
b PMCG vs CG
c
+Mat_sens 253 1.37 (0.97–1.93) 2.97 (1.19–7.43) 1.63 (1.15–2.31) 0.002 0.005
−Mat_sens 311 2.30 (1.64–3.22) 7.19 (3.77–13.69) 1.18 (0.86–1.61) 3.2 x10−10 0.30
a Number of families.
b P value for the comparison with the null model with no effects.
c P value for the comparison with the Child Genotype model.
CI indicates 95% confidence interval. All results correspond to the combined FLG mutations. Note that all unrelated cases and population-based controls
were excluded from this analysis due to missing maternal sensitization data.
doi:10.1371/journal.pgen.1005076.t005
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Here, the maternal genotype effect was not significant (S1 = 1.18; PMCG vs CG = 0.3) while the
child genotype effect was strong (R1 = 2.3; Pnull = 9.9 x 10
−11). This observation was confirmed
by a striking over-transmission of FLGmutations in the TDT (T:U = 169:68, P = 5.3 x 10−8). In
concordance with the different rates of mutation transmission observed in both groups, the fre-
quency of FLGmutations was significantly higher in AD-children of non-allergic mothers
(mutation frequency 0.16 and 0.11 in affected children of −Mat_sens and +Mat_sens families,
respectively; OR = 1.48; P = 0.005; Table 6).
Discussion
We report here that maternal loss-of-function mutations in FLG directly influence AD risk in
the offspring independently of the child’s own genotype. Importantly, this maternal effect was
observed consistently for all different FLGmutations tested and in 2 independent populations.
Given that genomic imprinting and maternal genotype effects can lead to similar patterns of
parent-of-origin effects [14], we specifically modelled both scenarios. Although we cannot
completely exclude an imprinting effect, our data supports a direct maternal genotype effect of
FLGmutations. This is consistent with the lack of known imprinted genes in the 1q21.3 geno-
mic region containing FLG [25].
It is not obvious how maternal mutations in a skin-barrier gene can influence the child’s
phenotype. However, given that filaggrin deficiency promotes specific sensitization, we hy-
pothesized that systemic immune responses may play a role in the FLGmaternal effect. Our
observation that the FLGmaternal effect is significant only in the group of sensitized mothers
supports this hypothesis and indicates that FLGmutations in allergic mothers act as a strong
environmental risk factor for AD in the child.
The importance of prenatal mother-child interaction in shaping the child’s immune pheno-
type is highlighted by studies in pregnant mice: while the induction of Th2 immune responses
increased susceptibility to allergic asthma in the offspring, a protective effect was observed
upon induction of Th1 responses, emphasizing the importance of maternal immune status
during pregnancy [30–32]. Supporting evidence in humans arise from epidemiological studies
showing that exposure to a microbial-rich farm environment during pregnancy protects chil-
dren from the development of allergic diseases [33]. It is unknown how this “immunological
imprinting”may be transmitted from mother to child, but animal and human studies suggest
the induction of epigenetic modifications in relevant immune cells in the offspring [31,34]. Fu-
ture large population-based studies with parental DNA, data on maternal allergic sensitization
and biological material available for epigenetic analysis will be required to further explore this
interesting hypothesis.
Table 6. TDT analysis stratified by maternal specific sensitization.
Transmission Disequilibrium Test (TDT) Allelic test in children d
Group na T / Ub ORc P Mut freq OR (P)
+Mat_sens 253 97 / 65 1.49 0.04 0.11 1
−Mat_sens 311 169 / 68 2.49 5.3 x10−8 0.16 1.48 (0.005)
a Number of families.
b Number of transmitted (T) and un-transmitted (U) alleles. Allele counts are referred to the combined FLG mutations.
c Odds ratio calculated as the ratio of transmitted versus un-transmitted alleles.
d Comparison of allelic frequency between AD-affected children of the −Mat_sens versus the +Mat_sens families.
doi:10.1371/journal.pgen.1005076.t006
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A recent mouse study found that parent-of-origin effects are widespread and account for an
unexpectedly large proportion of complex trait heritability [35]. This is supported by human
studies demonstrating that the parental origin of an allele inherited by the offspring can affect
disease susceptibility to complex diseases [12,13,36–38]. However, evidence for the existence of
maternal genotype effects, which occur without transmission of the risk allele to the offspring,
comes mainly from animal studies analysing the effect of maternal gene knockouts in wild-
type offspring [39]. Examples of such effects in humans are scarce and refer to rare congenital
malformations [40,41]. The present work is, to our knowledge, the first report of a large mater-
nal genotype effect in a common human disease. Notably, the magnitude of the maternal effect
(RR = 1.5) was consistent in both data sets and exceeded that reported for most AD genetic
risk factors identified to date.
Interestingly, AD is commonly the first manifestation of allergic disease and filaggrin defi-
ciency is a risk factor for the transition from AD to other atopic diseases such as food allergy,
hay fever, and asthma [5,16]. Thus, it is tempting to speculate that maternal FLGmutations
may influence the risk of a much wider range of allergic disorders.
This and other studies provide proof-of-principle that associations originally discovered by
case-control analysis can arise as a consequence of parent-of-origin effects, although with an
underestimation of the effect size due to inaccurate genetic modelling [12]. Family-based stud-
ies re-evaluating previously identified susceptibility loci will enable the identification of parent-
of-origin effects and help characterize part of the missing heritability in complex traits.
Methods
Ethics statement
The study was carried out in accordance to the approval of the ethics commission of the Char-
ité—Universitätsmedizin Berlin (ref EA2/054/10) and following the guidelines of the declara-
tion of Helsinki. Informed consent was obtained from all probands or their legal guardians.
Subjects
We investigated samples originating from European family-based and population-based stud-
ies. All samples were divided, according to the country of origin, into a Central and a Northern
European study population (Table 1).
The GENUFAD study (Genetic Analysis of Nuclear Families with Atopic Dermatitis) re-
cruited complete nuclear families with at least two children affected with early-onset (<2 years
of age) and moderate to severe AD as previously described [20]. A doctor’s diagnosis of AD
was made according to standard criteria [42]. The GENUFAD study contributed 522 complete
German nuclear families to the Central European study and 32 Swedish families to the North-
ern European data set. A large proportion of these families have been reported in previous
studies [16,43].
The MAS (Multicenter Allergy Study) is a previously described population-based birth co-
hort in which 1314 German infants were followed since 1990 to investigate the epidemiology
of allergic diseases [44]. The diagnosis of AD was made as previously described [16]. 112 Ger-
man MAS trios, consisting of a child with AD and both parents, were included in the Central
European study.
The ETAC (Early Treatment of the Atopic Child) is a European study which recruited in-
fants diagnosed with AD in their first year of life into a randomized, double blind, placebo con-
trolled trial on the efficacy of cetirizine in the prevention of asthma [45]. Children with early
onset and moderate to severe disease were selected for the present study when parental DNA
was available. The ETAC study contributed 21 Swedish trios to the Northern European study.
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Additionally, 125 ETAC trios from different European countries were included in the Central
European study (48 from the Netherlands, 23 from Italy, 20 from the UK, 15 from France, 13
from the Czech Republic, and 6 from Germany).
A previous study from Sweden contributed 397 families to the Northern European study
group [17]. This included 272 complete affected sib pair families with AD diagnosed according
to the U.K. Working Party’s Diagnostic Criteria [46]. The remaining 125 families were incom-
plete nuclear families including mother-child or father-child pairs.
In all family-based studies, information regarding the parental history of AD was obtained
by a questionnaire at the time of family recruitment. The analysis shown in S6 Table was per-
formed in families in which both parents had a negative history of AD. Families in which one
or both parents had a positive or unknown disease history were excluded.
As described below, the analytical methods used allowed the incorporation of unrelated in-
dividuals to increase power. Thus, the Central European study also included previously pub-
lished FLG genotypes of 772 unrelated German AD cases and 373 German controls from a
previous GWAS [43]. In addition, we genotyped FLGmutations in 375 German children with
AD diagnosed at a tertiary care center for pediatric allergy at Charité Universitätsmedizin Ber-
lin. Also, previously published FLG genotype counts of 2,963 population-based German indi-
viduals from the International Study of Asthma and Allergies in Childhood II Study [47] were
included. Likewise, in our Northern European study population we included genotypes of the 3
most prevalent FLGmutations (c.2282del4, p.R501X and p.R2447X) previously reported in the
Swedish population-based BAMSE cohort [22]. The rarest FLGmutation (p.S3247X) was not
available in the BAMSE dataset.
Data on specific allergic sensitization was available in a large proportion of mothers from
the GENUFAD and MAS studies. Plasma levels of specific IgE against grass and birch pollen,
ribwort, cat and dog dander, mold (Cladosporidium herbarum, Alternaria tenuis), hen’s egg,
cow’s milk, fish, peanut, and house dust mite were determined using CAP-RAST-FEIA (Phar-
macia). A mother was defined as sensitized if specific IgE0.7 kU/l (CAP2) to at least one al-
lergen was detected.
Genotyping of FLGmutations
Genomic DNA was prepared from whole blood by standard methods. The FLG c.2282del4 var-
iant was analyzed with fluorescence-based semiautomated genotyping [16] and the FLG p.
R501X, p.R2447X and p.S3247X mutations with Taqman allelic discrimination (Applied Bio-
systems, Foster City, California, USA) as previously described [4]. Genotyping of p.R2447X in
the Northern European families was performed using a fluorescent Kaspar assay (KASP-By-
Design genotyping assays, LGC group, Teddington, UK). Genotyping with Taqman and Kas-
par was performed using a ViiA 7 Real-Time PCR System (Applied Biosystems, Foster City,
California, USA). When analyzing the rare p.R2447X and p.S3247X mutations, a sample
known to be a mutation carrier was included on each genotyping plate as a positive control.
The FLGmutations are named according to the nomenclature recommendations by den
Dunnen and Antonarakis [48]. The positions of the mutations in the cDNA refer to the A of
the ATG-translation initiation codon of NM_002016.1.
Statistical analysis
The PREMIM and EMIM tools were used to test for imprinting and maternal genotype effects
of the FLGmutations [18,19]. First, the PREMIM tool was used to classify each trio according
to the number of copies of FLGmutations carried by mother, father, and affected child. Incom-
plete nuclear families, unrelated AD cases, and population-based samples were also included in
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the analysis to increase the power to detect parent-of-origin effects [18,19]. Since the EMIM
analysis is based on the assumption that the genotype frequencies in controls correspond to
those in the general population, all population-based controls were included in the analysis
irrespectively of disease status. Starting values for allele frequencies of the FLGmutations in
the study population (including controls) were estimated with PREMIM (–a option).
The trios were analyzed using the EMIM tool, which uses a multinomial modelling ap-
proach to estimate genotype relative risk parameters on the basis of observed counts of geno-
type combinations in case-parent trios. The following parameters influencing the disease risk
in the child were modelled with EMIM:
• R1 (R2), the factor by which an individual’s disease risk is multiplied if they carry one (two)
risk alleles at a given locus.
• S1 (S2), the factor by which an individual’s disease risk is multiplied if the mother carries one
(two) risk alleles at that locus.
• Im (Ip) the factor by which an individual’s disease risk is multiplied if inheriting a risk allele
from the mother (or father).
• γ11 (interaction term), the factor by which an individual’s disease risk is multiplied if both
mother and child have 1 copy of the risk allele.
Previous data indicated that FLGmutations do not fit an additive genetic model, since the
risk of AD in the homozygous carriers is too high. Thus, instead of using the default EMIM set-
tings assuming an additive model we choose to independently estimate the R1 and R2 parame-
ters. Modelling of maternal genotype effects was done using the default additive model. All
analyses were performed under the “conditional on exchangeable parental genotype” (CEPG)
assumption. This assumption should protect from potential biases in parameter estimation due
to the inclusion of families recruited through multiple affected individuals, at the cost of re-
duced power to detect parent-of-origin effects compared to assuming only Hardy-Weinberg
equilibrium [18,19]. A step-by-step analysis was performed by including additional risk param-
eters in the model as indicated in S9 Table.
Maximum likelihood estimates were obtained from each model and a likelihood ratio test
was performed to assess the significance among nested models. Note that it is not possible to
directly compare the MCG and Im models in a likelihood ratio test, since they are not nested.
However, they can be compared indirectly by comparison to the full model (Table 4).
In order to test for genetic interaction between the child and the maternal genotypes we in-
cluded and interaction term in the model (γ11). This parameter estimates the factor by which
an individual’s disease risk is multiplied if both mother and child have one copy of the risk al-
lele. A likelihood ratio test comparing the Maternal Child Genotype (MCG) and the MCG-In-
teraction model was then performed (see S10 Table).
A meta-analysis of the results from the Central and Northern European populations was
performed using METAL [23]. The inverse variance method was used and the corresponding
betas and standard errors were obtained from the EMIM summary file. The meta-analysis was
performed on the single risk parameters estimates (R1, R2, S1 or Im) from each model. An
analysis of heterogeneity was also performed with METAL in order to evaluate if the observed
effect sizes were homogeneous across datasets.
In order to increase power in the main analysis we allowed the inclusion of all affected off-
spring available in each family which were considered as independent trios (-xa option in PRE-
MIM). This may lead to biased results when using large pedigrees but it is unlikely to have a
large effect in our study since most families had only 1 or 2 affected children. In order to
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exclude this potential bias we repeated the analysis including one affected child per family
(omitting the −xa option in PREMIM; S8 Table).
The Transmission Disequilibrium Test (TDT) was performed with PLINK [49]. In order
to account for multiple affected offspring within families, empirical p-values were calculated
with the—tdt—perm option, which flips the allele transmitted from parent to offspring with
50:50 probability. Allelic effects were calculated with PLINK—assoc using the offspring of
the +Mat_Sens as controls and those from the −Mat_Sens as cases.
Haplotype frequencies on the central European Study were calculated with FAMHAP [50],
which computes maximum-likelihood estimates obtained with the expectation-maximization
algorithm.
Supporting Information
S1 Fig. Tissue expression pattern of FLG from BioGPS. Data from the BioGPS Portal where
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(TIF)
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where mRNA was quantified by Next generation Sequencing. [27]
(TIF)
S1 Table. FLG loss-of-function mutations in the ExAC project. Only high quality mutations
were considered (filter = pass). a Human genome build GRCh37.p13 (chromosome 1). b Alias
used in this manuscript. c Allele frequency in the combined set of 61,486 unrelated individuals.
d Alternative allele count of genotypes in the combined population e Total number of called ge-
notypes in the combined population. Data was accessed on December 12, 2014.
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